Demise of a Wall Street Star

Neuromedical Systems, once a rising star on Wall Street and the leader of a crop of new Pap smear automation companies, filed for bankruptcy in March. One of its chief competitors, AutoCyte Inc. is bidding to buy the company's intellectual property. AutoCyte then has an agreement with NeoPath Inc. to share ownership of the assets and in turn Neopath will pay approximately half of the purchase price of about $12 million to AutoCyte. The AutoCyte deal has to be approved by the US bankruptcy court.

Neuromedical Systems Inc. 's bankruptcy filing in March is a cautionary tale of what can go wrong with young, seemingly "hot" medical device companies. Only a few years ago, NSI was at the forefront of a group of innovators seeking to reduce the error rate of Pap smear screening by automating some or all of the process. Its initial public offering [See Deal] was the most successful diagnostic IPO of 1995. Others with competing approaches were also attracting a lot of investor attention, but none came close to matching the company's $400 million valuation. NSI's downfall is a typical example of the disappointments that have made the current financing market for medical start-ups so miserable.

NSI's computer-based screening system, PapNet, was one of the first of the new Pap smear technologies to get FDA approval...

More from Business Strategy

More from In Vivo

Rising Leaders 2025: Doxie Jordan, From UNC Graduate To Global Market Strategist

 
• By 

Bristol Myers Squibb executive Doxie Jordan discusses his path to global commercial leadership and the principles guiding pharmaceutical market strategy

Podcast: Brain+ CEO Discusses “Groundbreaking” Potential Of CST Assistant For Dementia Patients

 

Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.

Behind The Buyout: Dispatches From The Dealmaking Table

 
• By 

In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.